Orchid Pharma Limited (ORCHPHARMA) has recently unlocked two massive, fundamental corporate and commercial catalysts that have triggered significant upward momentum for the stock:💊 The $178 Million Russian Commercialization Deal (July 2026): Orchid Pharma signed a major, exclusive licensing and supply agreement with Russian pharmaceutical giant Pharmasyntez JSC to commercialize its patented flagship antibiotic, Exblifep (a novel drug treating severe hospital infections and UTIs). Pharmasyntez will handle exclusive registration and marketing across Russia, while Orchid will handle sole manufacturing and supply. This 10-year deal represents a potential $178 million revenue opportunity, leveraging the fact that Exblifep is already approved by the USFDA and EMA. ⚖️ Final NCLT Sanction for Dhanuka Laboratories Merger (June–July 2026): The National Company Law Tribunal (NCLT) issued its final order approving the structural amalgamation of promoter entity Dhanuka Laboratories Limited into Orchid Pharma. The company fixed July 23, 2026, as the official Record Date for alloting shares to Dhanuka’s shareholders. Backdated to an appointed date of April 1, 2024, this consolidation unites their API research assets and product portfolios, with management targeting combined forward annual revenues of ₹1,400–₹1,500 crore and EBITDA of ₹200–₹250 crore. These catalysts—bridging large-scale global product commercialization with massive domestic operational consolidation—have significantly strengthened Orchid Pharma's medium-term earnings outlook.
Publikasi terkait
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.
Publikasi terkait
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.